Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity
The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. ...
Tag: GLP-1
Semaglutide improves heart health and reduces weight in obese patients, but with side effects
Study shows that semaglutide not only aids in weight loss but also slashes heart failure risk by 76% in overweight ...
GLP-1 receptor agonists show promise in treating substance use disorders
A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due ...
Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation
Study: Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. Image Credit: myskin / Shutterstock.com In a recent ...
Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management
In a recent review published in the journal Frontiers Endocrinology, researchers collate and elucidate recent clinical and pathophysiological knowledge on ...
Natural compound found in olives can lower blood sugar levels and promote weight loss
Findings from a new mouse study suggest that elenolic acid, a natural compound found in olives, can lower blood sugar ...
Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024
Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions ...
Anti-obesity medications slash heart disease risk in obese patients, study finds
Obesity is a major cause of illness and death, mainly due to cardiovascular disease (CVD), which claims about 18 million ...
Sustainable weight loss with personalized semaglutide dosing
New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits ...
How safe are GLP-1R agonists in early pregnancy?
A new study published in JAMA Internal Medicine examines the safety of glucagon-like peptide 1 (GLP-1) receptor agonists, along with ...
